Promotie onderzoek

KNMP stelt wetenschappelijk onderzoek voorop. Hier kunt u de meest recente onderzoeken vinden.
Er zijn15resultaten gevonden
Farmacogenetica

Treatment optimization and pharmacogenetics of systemic and intraperitoneal chemotherapy in colorectal cancer

  • Universiteit Leiden Universitair Medisch Centrum
  • Promovendus Emma Hulshof
  • Promoters Henk-Jan Guchelaar
  • Co-Promoters Hans Gelderblom Maarten Deenen
  • Jaar 2019 - 2022

Het onderzoek is gericht op optimalisatie van de behandeling van colorectaal kanker middels farmacogenetica en farmacokinetische studies. 

Farmacogenetica

Pharmacogenetics of platinumbased chemotherapy in non-small cell lung cancer

  • Universiteit Universiteit Utrecht
  • Promovendus Corine de Jong
  • Promoters Toine Egberts
  • Co-Promoters Judith Herder Vera Deneer
  • Jaar 2018 - 2022

Identificeren van biomarkers, waaronder genetische variaties, die geassocieerd zijn met de effectiviteit en toxiciteit van platinumhoudende chemotherapie in de behandeling van patiënten met niet-kleincellig longcarcinoom.

Geneesmiddelregulering

Safety assessment and use of biologicals/ biosimilars in clinical practice

  • Universiteit Universiteit Utrecht
  • Promovendus Rosanne Meijboom
  • Promoters Toine Egberts Bert Leufkens
  • Co-Promoters Thijs Giezen Helga Gardarsdottir
  • Jaar 2018 - 2022

The aim of this project is to provide insight in the use of biologicals, including biosimilars, in clinical practice and add to the safe and effective use of these agents. We also provide guidance on the implementation of biosimilars in clinical practice from the perspective of different stakeholders including prescribers, pharmacists and patients.

Farmaco-economie

Advances in chemo-efficiency

  • Universiteit Erasmus Medisch Centrum Rotterdam
  • Promovendus Ruben Malmberg
  • Promoters Stefan Sleijfer Prof. Dr. Birgit Koch
  • Co-Promoters Roelof van Leeuwen
  • Jaar 2020 - 2024
  1. The safety of short hydration during cisplatin chemoradiation in head and neck cancer patients: a randmized controlled trial.
  2. The feasibility of 6 monthly gosereline injections in prostate cancer patients. 
  3. Nivolumab administration through an elastomeric pump versus iv bag administration: a patient preference study.
Farmaco-economie

Effectiveness and cost-effectiveness of pharmaceutical pulmonary care in Indonesia

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Deni Iskander
  • Promoters Prof. dr. Maarten Postma
  • Co-Promoters Job van Boven
  • Jaar 2020 - 2024

Farmaceutische zorg bij longziekten in Indonesie.

Farmaco-economie

Economic evaluations of novel hospital dispensed drugs for lung cancer and ILD

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Lotte Westerink
  • Promoters Prof. dr. Maarten Postma
  • Co-Promoters Job van Boven Cornelis Boersma
  • Jaar 2019 - 2023

Economische evaluaties van dure longmedicatie bij long kanker en ILD/IPF.

Geneesmiddelregulering

Healthcare professionals’ views on clinical relevance of new medicines in primary care

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Marloes Dankers
  • Promoters prof. dr. Liset van Dijk prof. dr. Aukje Mantel-Teeuwisse
  • Co-Promoters dr. Marjorie Nelissen
  • Jaar 2019 - 2023

New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice. 

Pagina 1 van 3